EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)Open Access

Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR -Variant Non–Small Cell Lung Cancer

HARMONi-A Study Investigators, Wenfeng Fang, Yuanyuan Zhao, Yongzhong Luo, Runxiang Yang, Yan Huang, Zhiyong He, Hui Zhao, Mingjun Li, Kai Li, Qibin Song, Xiaobo Du und 48 weitere

JAMA · 28.07.2026 · 336 (4) · 306

DOI: 10.1001/jama.2026.7745 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JAMA, erschienen am 28.07.2026. Verfasst von HARMONi-A Study Investigators und 59 weiteren Autor:innen. Beteiligte Einrichtung: Sun Yat-sen University Cancer Center, Guangzhou, China. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Patients with epidermal growth factor receptor ( EGFR ) gene variant nonsquamous non–small cell lung cancer (NSCLC) who have disease progression after prior EGFR tyrosine kinase inhibitor (TKI) therapy have limited treatment options, creating a need for more effective subsequent therapies.

Objective

To provide final overall results of a trial assessing whether adding ivonescimab (a bispecific antibody targeting programmed cell death protein 1 and vascular endothelial growth factor) to chemotherapy improves overall survival in this population. Design, Setting, and Participants Randomized, double-blind, placebo-controlled phase 3 trial conducted at 55 sites in China. From January 25 to November 2, 2022, a total of 322 adult patients with locally advanced or metastatic EGFR -variant nonsquamous NSCLC who had received prior EGFR-TKI therapy were enrolled. The data cutoff date was April 12, 2025.

Interventions

Patients were randomized 1:1 to receive ivonescimab (20 mg/kg; n = 161) or placebo (n = 161) plus chemotherapy with pemetrexed and carboplatin once every 3 weeks for 4 cycles, followed by maintenance therapy. Main Outcomes and Measures This final results report focuses on overall survival, the key secondary end point, tested in a hierarchical manner (the primary end point was progression-free survival assessed by an independent radiology review committee).

Results

The 322 enrolled patients had a median age of 59.4 years, and 51.6% were female. During a median follow-up of 32.5 months, ivonescimab plus chemotherapy improved overall survival compared with chemotherapy alone (median survival, 16.8 months vs 14.1 months; stratified hazard ratio, 0.74; 95% CI, 0.58-0.95; P = .02). The absolute difference in median overall survival was 2.7 months. Estimated 30-month survival rates were 29.1% (95% CI, 22.1%-36.4%) with ivonescimab and 18.4% (95% CI, 12.8%-24.8%) with placebo. Grade 3 or higher treatment-emergent adverse events occurred in 67.1% and 54.7% of patients receiving ivonescimab and placebo, respectively. Conclusions and Relevance Ivonescimab plus chemotherapy provided a statistically significant and clinically meaningful improvement in overall survival with an acceptable safety profile in patients with EGFR -variant NSCLC after EGFR-TKI therapy. Trial Registration ClinicalTrials.gov Identifier: NCT05184712

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungLung NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedCarboplatinDouble-Blind MethodErbB ReceptorsPemetrexedProgrammed Cell Death 1 ReceptorChinaTyrosine Kinase InhibitorsVascular Endothelial Growth Factor AProgression-Free SurvivalInfusions, Intravenous

Substanzen

Antibodies, BispecificCarboplatinEGFR protein, humanErbB ReceptorsPemetrexedProgrammed Cell Death 1 ReceptorTyrosine Kinase InhibitorsVascular Endothelial Growth Factor A

Autor:innen und Institutionen

  • Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Hunan Cancer Hospital, Changsha, China.
  • The Third Affiliated Hospital of Kunming Medical University (Yunnan Cancer Hospital), Kunming, China.
  • Fujian Provincial Tumor Hospital, Fuzhou, China.
  • The Second Hospital of Anhui Medical University, Hefei, China.
  • The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Zitieren

APA

HARMONi-A Study Investigators, Fang, W., Zhao, Y., Luo, Y., Yang, R., Huang, Y., He, Z., Zhao, H., Li, M., Li, K., Song, Q., Du, X., Sun, Y., Li, W., Sun, L., Wang, Z., Yang, K., Fan, Y., Liu, B., …, & Song, X. (2026). Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR -Variant Non–Small Cell Lung Cancer. JAMA, 336(4), 306. https://doi.org/10.1001/jama.2026.7745

Vancouver

HARMONi-A Study Investigators, Fang W, Zhao Y, Luo Y, Yang R, Huang Y, et al. Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR -Variant Non–Small Cell Lung Cancer. JAMA. 2026;336(4):306. doi:10.1001/jama.2026.7745

BibTeX
@article{HARMONiAStudyInvestigators2026,
  author = {HARMONi-A Study Investigators, HARMONi-A Study Investigators and Fang, Wenfeng and Zhao, Yuanyuan and Luo, Yongzhong and Yang, Runxiang and Huang, Yan and He, Zhiyong and Zhao, Hui and Li, Mingjun and Li, Kai and Song, Qibin and Du, Xiaobo and Sun, Yulan and Li, Wei and Sun, Longhua and Wang, Zhiyu and Yang, Kunning and Fan, Yun and Liu, Baogang and Zhao, Hongyun and Hu, Ying and Jia, Li and Xu, Shen and Yi, Tienan and Lv, Dongqing and Lan, Haitao and Li, Mengxia and Liang, Wenhua and Wang, Yongsheng and Yang, Hui and Jia, Yuming and Chen, Yuan and Lu, Junguo and Shi, Meiqi and Liu, Chunling and Zhou, Ming and Zhou, Jianya and Liu, Xianling and Zhou, Ningning and He, Ming and Dong, Xiaorong and Chen, Hualin and Chen, Yongxing and Su, Haichuan and Li, Xiaoling and Zhang, Zhihong and Yang, Lei and Liu, Ying and Chen, Likun and Hou, Xue and Zhang, Yu and Guo, Jun and Ma, Ruiqiang and Lu, Hong and Wu, Di and Feng, Weineng and Li, Wen and Huang, Jianan and Wang, Yan and Song, Xia},
  title = {Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR -Variant Non–Small Cell Lung Cancer},
  journal = {JAMA},
  year = {2026},
  volume = {336},
  number = {4},
  pages = {306},
  doi = {10.1001/jama.2026.7745}
}
Kostenlos starten →